Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - RenovaCare, Inc. | exh_321.htm |
| EX-31.2 - EXHIBIT 31.2 - RenovaCare, Inc. | exh_312.htm |
| EX-31.1 - EXHIBIT 31.1 - RenovaCare, Inc. | exh_311.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2021
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number 000-30156
| RENOVACARE, INC. | ||
| (Exact name of registrant as specified in its charter) |
| Nevada | 98-0384030 | |
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) |
| 4 Becker Farm Road, Suite 105 | ||
| Roseland, NJ 07068 | ||
| (Address of principal executive offices) |
888-398-0202
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: None
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| N/A | N/A | N/A |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company", and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | (Do not check if a smaller reporting company) | |
| Smaller reporting company | ☒ | Emerging Growth Company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in 12b-2 of the Exchange Act): Yes ☐ No ☒
As of May 6, 2021, the registrant had 87,352,364 shares of its common stock, par value $0.00001 per share, issued and outstanding.
RENOVACARE, INC.
FORM 10-Q
For The Quarter Ended March 31, 2021
TABLE OF CONTENTS
RENOVACARE, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
| March 31, | December 31, | |||||||
| 2021 | 2020 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | 5,607,845 | $ | 7,412,969 | ||||
| Prepaid expenses | 462,171 | 566,275 | ||||||
| Total current assets | 6,070,016 | 7,979,244 | ||||||
| Equipment, net of accumulated depreciation of $5,908 and $3,584, respectively | 36,315 | 38,640 | ||||||
| Intangible assets | 152,854 | 152,854 | ||||||
| Security Deposit | 7,995 | 7,995 | ||||||
| Right of Use Asset | 65,603 | 79,462 | ||||||
| Other Assets | 115,997 | 137,749 | ||||||
| Total assets | $ | 6,448,780 | $ | 8,395,944 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued liabilities | $ | 716,237 | $ | 1,237,437 | ||||
| Lease liability - current | 49,943 | 51,125 | ||||||
| Total current liabilities | 766,180 | 1,288,562 | ||||||
| Lease Liability - long term | 17,579 | 28,607 | ||||||
| Total liabilities | 783,759 | 1,317,169 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity | ||||||||
| Preferred stock: $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding | - | - | ||||||
| Common stock: $0.00001 par value; 500,000,000 shares authorized, 87,352,364 shares issued and outstanding at March 31, 2021 and December 31, 2020 | 874 | 874 | ||||||
| Additional paid-in capital | 35,949,570 | 36,846,082 | ||||||
| Retained deficit | (30,285,423 | ) | (29,768,181 | ) | ||||
| Total stockholders' equity | 5,665,021 | 7,078,775 | ||||||
| Total liabilities and stockholders' equity | $ | 6,448,780 | $ | 8,395,944 | ||||
(See accompanying notes to unaudited consolidated financial statements)
| 1 |
RENOVACARE, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2021 | 2020 | |||||||
| Revenue | $ | - | $ | - | ||||
| Operating expenses | ||||||||
| Research and development | 1,054,293 | 192,773 | ||||||
| General and administrative | (537,044 | ) | 1,035,566 | |||||
| Total operating expenses, net | 517,249 | 1,228,339 | ||||||
| Loss from operations | (517,249 | ) | (1,228,339 | ) | ||||
| Other income | ||||||||
| Interest income | 7 | 53,586 | ||||||
| Total other income | 7 | 53,586 | ||||||
| Net loss | $ | (517,242 | ) | $ | (1,174,753 | ) | ||
| Basic and Diluted Loss per Common Share | $ | (0.01 | ) | $ | (0.01 | ) | ||
| Weighted average number of common shares outstanding - basic and diluted | 87,352,364 | 87,352,364 | ||||||
(See accompanying notes to unaudited consolidated financial statements)
| 2 |
RENOVACARE, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)
| FOR THE THREE MONTHS ENDED MARCH 31, 2021 | Common Stock | Additional | Retained | Total Stockholders' | ||||||||||||||||
| Shares | Amount | Paid-in Capital | Deficit | Equity | ||||||||||||||||
| Balance, December 31, 2020 | 87,352,364 | $ | 874 | $ | 36,846,082 | $ | (29,768,181 | ) | $ | 7,078,775 | ||||||||||
| Stock based compensation due to common stock purchase options | - | - | 352,063 | - | 352,063 | |||||||||||||||
| Reversal of stock based compensation due to common stock purchase option cancellations | - | - | (1,248,575 | ) | - | (1,248,575 | ) | |||||||||||||
| Net loss for the three months ended March 31, 2021 | - | - | - | (517,242 | ) | (517,242 | ) | |||||||||||||
| Balance, March 31, 2021 | 87,352,364 | $ | 874 | $ | 35,949,570 | $ | (30,285,423 | ) | $ | 5,665,021 | ||||||||||
| FOR THE THREE MONTHS ENDED MARCH 31, 2020 | ||||||||||||||||||||
| Balance, December 31, 2019 | 87,352,364 | $ | 874 | $ | 32,378,833 | $ | (20,219,845 | ) | $ | 12,159,862 | ||||||||||
| Stock based compensation due to common stock purchase options | - | - | 465,763 | - | 465,763 | |||||||||||||||
| Net loss for the three months ended March 31, 2020 | - | - | - | (1,174,753 | ) | (1,174,753 | ) | |||||||||||||
| Balance, March 31, 2020 | 87,352,364 | $ | 874 | $ | 32,844,596 | $ | (21,394,598 | ) | $ | 11,450,872 | ||||||||||
(See accompanying notes to unaudited consolidated financial statements)
| 3 |
RENOVACARE, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2021 | 2020 | |||||||
| Cash flows used in operating activities | ||||||||
| Net loss | $ | (517,242 | ) | $ | (1,174,753 | ) | ||
| Adjustments to reconcile net loss to net cash flows used in operating activities: | ||||||||
| Depreciation expense | 2,324 | - | ||||||
| Stock based compensation expense | (874,760 | ) | 465,763 | |||||
| Amortization of right of use asset | 13,859 | |||||||
| Changes in operating assets and liabilities: | ||||||||
| (Increase) decrease in prepaid expenses and other assets | 104,104 | (216,720 | ) | |||||
| Increase (decrease) in accounts payable | (521,199 | ) | 125,272 | |||||
| Increase (decrease) in accounts payable - related parties | - | 5,287 | ||||||
| Increase (decrease) in lease liability | (12,210 | ) | - | |||||
| Net cash flows used in operating activities | (1,805,124 | ) | (795,151 | ) | ||||
| Cash flows from investing activity | ||||||||
| Decrease (increase) in security deposit | - | (7,995 | ) | |||||
| Net cash flows from investing activity | - | (7,995 | ) | |||||
| Decrease in cash | (1,805,124 | ) | (803,146 | ) | ||||
| Cash at beginning of period | 7,412,969 | 12,185,248 | ||||||
| Cash at end of period | $ | 5,607,845 | $ | 11,382,102 | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Interest paid in cash | $ | - | $ | - | ||||
| Income taxes paid in cash | $ | - | $ | - | ||||
(See accompanying notes to unaudited consolidated financial statements)
| 4 |
RENOVACARE, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
Note 1. Basis of Presentation, Organization, Overview of Operations, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share
Basis of Presentation
The accompanying unaudited interim consolidated financial statements of RenovaCare, Inc. and Subsidiary (the “Company”) as of March 31, 2021, and for the three months ended March 31, 2021 and 2020 have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. These Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2020 included in our Annual Report on Form 10-K filed with the SEC on March 31, 2021.
The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Consolidated Financial Statements and accompanying disclosures. Actual results may differ from those estimates. The accompanying unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s consolidated financial position as of March 31, 2021, results of operations, stockholders’ equity and cash flows for the three months ended March 31, 2021 and 2020. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.
Organization
RenovaCare, Inc. was incorporated on July 14, 1983 in the State of Utah under the name Far West Gold, Inc., and changed its domicile to Nevada in 1997. On January 7, 2014, the Company changed its name at the time from “Janus Resources, Inc.” to “RenovaCare, Inc.” so as to more fully reflect its current operations and business, and changed its trading symbol to “RCAR” effective as of January 9, 2014.
The Company has an authorized capital of 500,000,000 shares of $0.00001 par value common stock, of which 87,352,364 shares are outstanding as of March 31, 2021, and 10,000,000 shares of $0.0001 par value preferred stock, of which none are outstanding.
Overview of Operations
RenovaCare, Inc., through its wholly owned subsidiary, RenovaCare Sciences Corp. is a development-stage company focusing on the research, development and commercialization of autologous (using a patient’s own cells) cellular therapies that can be used for medical and aesthetic applications.
On July 12, 2013, the Company completed the acquisition of its flagship technologies (collectively, the “CellMistTM System”), along with associated United States patent applications and two foreign patent applications, all of which have been granted. The CellMist™ System is a cell isolation procedure that enzymatically renders stem cells from the patient’s own skin or other tissues. The resulting stem cell suspension is administered topically with our SkinGun™ spray device as a cell therapy onto wounds including burns to facilitate healing.
In August 2019, the Company was awarded a continuation of a patent allowing the Company’s novel solution sprayer device (the “SkinGunTM”) to be used to spray all varieties of tissues and cells, thus allowing for its potential application in the regeneration of tissues and organs, beyond skin; and, in November 2020, the Company was issued two new patents encompassing improvements to the SkinGun™, expanding its potential application beyond the surgical setting into the field, and allowing the use of liquid suspension solutions to include drugs, hormones, and other useful agents.
| 5 |
Improvements in the design and efficiency of the CellMist™ System including a closed, automated cell isolation device and the SkinGun™ spray device are in development with StemCell Systems (Berlin, Germany), the Company’s R&D innovation partner. The Company is adapting its core technologies for possible use in other clinical indications. The Company is also developing the cell isolation and spray gun devices as stand-alone 510 (k)-cleared products for isolation of cells from other tissues and spraying other solutions of medical importance.
The Company does not have any commercialized products. The Company's activities have consisted principally of performing research and development activities and raising capital to support such activities. The Company has enlisted the assistance of several Contract Manufacturing Organizations (CMO) to manufacture clinical supplies including components of the CellMist System™ and the electronic SkinGun™ spray devices in compliance with FDA’s guidance for current Good Manufacturing Practices (cGMP) and Contract Research Organizations (CRO) to test and validate the Company’s products and processes and to conduct clinical trials that evaluate initially the safety and feasibility of an autologous skin cell therapy using the Company’s products to facilitate burn wound healing. These development activities are subject to significant risks and uncertainties, including possible failure of preclinical and clinical testing. The Company has not generated any revenue and has sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues development of its products and technologies and expects that it will need to raise additional capital through partnerships or the sale of its securities to accomplish its business plan. Failing to secure such additional funding before achieving sustainable revenue and profit from operations poses a significant risk. The Company's ability to fund the development of its cellular therapies depends on the amount and timing of cash receipts from future financing activities. There can be no assurance as to the availability or terms upon which such financing and capital might be available. Additionally, there is significant uncertainty relating to the full impact of the COVID-19 pandemic on the Company’s operations and capital requirements. Should financing when needed be unavailable or prohibitively expensive or the COVID-19 pandemic continue, it may adversely affect the Company’s ability to (i) retain employees and consultants; (ii) obtain additional financing on terms acceptable to the Company, if at all; (iii) delay regulatory submissions and approvals; (iv) delay, limit or preclude the Company from securing clinical study sites; (v) delay, limit or preclude the Company from achieving technology or product development goals, milestones, or objectives; and (vi) preclude or delay entry into joint venture or partnership arrangements. The occurrence of any one or more of such events may affect the Company’s ability to continue on its pathway to commercialization of its technology or products.
Liquidity
As of March 31, 2021, the Company had $5,607,845 of cash on hand and cash equivalents, and working capital of $5,303,836. As a result, the Company believes it currently has sufficient cash to meet its funding requirements over the next twelve months following the issuance of this Quarterly Report on Form 10-Q. However, the Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it may need to raise additional capital to accomplish its business plan over the next several years. There can be no assurance as to the availability or terms upon which such financing and capital might be available. See “Overview of Operations” above.
Additionally, there is significant uncertainty relating to the full impact of the COVID-19 pandemic on the Company’s operations and capital requirements. Should financing when needed be unavailable or prohibitively expensive or the COVID-19 pandemic continue, it may adversely affect the Company’s ability to (i) retain employees and consultants; (ii) obtain additional financing on terms acceptable to the Company, if at all; (iii) delay regulatory submissions and approvals; (iv) delay, limit or preclude the Company from the operation of clinical study sites and testing laboratories; (v) delay, limit or preclude the Company from achieving technology or product development goals, milestones, or objectives; and (vi) preclude or delay entry into joint venture or partnership arrangements. The occurrence of any one or more of such events may affect the Company’s ability to continue on its pathway to commercialization of its technology or products.
| 6 |
Recent Accounting Standards
Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification.
The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion other than as discussed above. The Company believes that none of the new standards will have a significant impact on the financial statements.
Earnings (Loss) Per Share
The Company presents both basic and diluted earnings per share ("EPS") amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive.
Following is the computation of basic and diluted net loss per share for the three months ended March 31, 2021 and 2020:
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2021 | 2020 | |||||||
| Basic and Diluted EPS Computation | ||||||||
| Numerator: | ||||||||
| Loss available to common stockholders' | $ | (517,242 | ) | $ | (1,174,753 | ) | ||
| Denominator: | ||||||||
| Weighted average number of common shares outstanding | 87,352,364 | 87,352,364 | ||||||
| Basic and diluted EPS | $ | (0.01 | ) | $ | (0.01 | ) | ||
| The shares listed below were not included in the computation of diluted losses | ||||||||
| per share because to do so would have been antidilutive for the periods presented: | ||||||||
| Stock options | 3,164,999 | 2,938,071 | ||||||
| Warrants | 12,296,912 | 13,106,912 | ||||||
| Total shares not included in the computation of diluted losses per share | 15,461,911 | 16,044,983 | ||||||
Note 2. Assets – Intellectual Property
On July 12, 2013, the Company, together with its wholly owned subsidiary, RenovaCare Sciences, entered into an asset purchase agreement (“APA”) with Dr. Jörg Gerlach, MD, PhD, pursuant to which RenovaCare Sciences purchased all of Dr. Gerlach’s rights, title and interest in the CellMistTM System. Acquisition related costs amounted to $52,852 and were capitalized together with the cash payment upon the closing of the transaction in July 2013 of $100,002. Intangible assets amounted to $152,854 as of December 31, 2020 and 2019.
| 7 |
Note 3. Prepaid Expenses
Prepaid expenses consist of the following:
| March 31, | December 31, | |||||||
| 2021 | 2020 | |||||||
| Prepaid insurance | $ | - | $ | 54,180 | ||||
| Prepaid stock options for services | 87,001 | 86,999 | ||||||
| Prepaid professional fees | 65,000 | 65,000 | ||||||
| Prepaid research and development expense | 289,746 | 289,746 | ||||||
| Other prepaid costs | 20,424 | 70,350 | ||||||
| Total prepaid expenses | $ | 462,171 | $ | 566,275 | ||||
Note 4. Common Stock and Warrants
Common Stock
At March 31, 2021, the Company had 500,000,000 authorized shares of common stock with a par value of $0.00001 per share, 87,352,364 shares of common stock outstanding and 16,593,266 shares reserved for future issuances under the Company’s 2013 Long-Term Incentive Plan (the “2013 Plan”) as adopted and approved by the Company’s Board of Directors (the “Board”) and stockholders on June 20, 2013 and ratified by the Company’s stockholders on November 15, 2013, that provides for the grant of stock options to employees, directors, officers, and consultants. See “Note 7. Stock Options” for further discussion.
During the three months ended March 31, 2021 and 2020, the Company did not have any common stock transactions.
Warrants
The Company has issued warrants to purchase common stock at various exercise prices in connection with loan agreements and private placements. The following table summarizes information about warrants outstanding at March 31, 2021 and December 31, 2020:
| Shares of Common Stock Issuable from Warrants Outstanding as of | Weighted | |||||||||||||
| March 31, | December 31, | Average | ||||||||||||
| Description | 2021 | 2020 | Exercise Price | Expiration | ||||||||||
| Series E | 584,416 | 584,416 | $ | 1.54 | September 8, 2021 | |||||||||
| Series F | 7,246 | 7,246 | $ | 3.45 | February 23, 2022 & March 9, 2022 | |||||||||
| Series G | 460,250 | 460,250 | $ | 2.68 | July 21, 2022 | |||||||||
| Series H | 910,000 | 910,000 | $ | 2.75 | October 16, 2022 | |||||||||
| Series I | 10,335,000 | 10,335,000 | $ | 2.00 | November 26, 2025 | |||||||||
| Total | 12,296,912 | 12,296,912 | ||||||||||||
Note 5. Stock Options
On June 20, 2013, the Company’s Board adopted the 2013 Long-Term Incentive Plan and on November 15, 2013, a stockholder owning a majority of the Company’s issued and outstanding stock approved adoption to the 2013 Plan. Pursuant to the terms of the 2013 Plan, an aggregate of 20,000,000 shares of the Company’s common stock have been reserved for issuance to the Company’s officers, directors, employees and consultants in order to attract and hire key technical personnel and management. Options granted to employees under the 2013 Plan, including directors and officers who are employees, may be incentive stock options or non-qualified stock options; options granted to others under the 2013 Plan are limited to non-qualified stock options. As of March 31, 2021, there were 16,593,266 shares available for future grants.
| 8 |
The 2013 Plan is administered by the Board or a committee designated by the Board. Subject to the provisions of the 2013 Plan, the Board has the authority to determine the officers, employees and consultants to whom options will be granted, the number of shares covered by each option, vesting rights and the terms and conditions of each option that is granted to them; however, no person may be granted options to purchase more than 2,000,000 shares in any one fiscal year under the 2013 Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed $100,000. Options granted pursuant to the 2013 Plan are exercisable no later than ten years after the date of grant.
The exercise price per share of common stock for options granted under the 2013 Plan is the fair market value of the Company's common stock on the date of grant, using the closing price of the Company's common stock on the last trading day prior to the date of grant, except for incentive stock options granted to a holder of ten percent or more of the Company's common stock, for whom the exercise price per share will not be less than 110% of the fair market value. No option can be granted under the 2013 Plan after June 20, 2023.
The following table summarizes stock option activity for the three months ended March 31, 2021:
| Number of Options | Weighted Average Exercise Price ($) | Weighted Average Remaining Contractual Term (years) | Aggregate Intrinsic Value ($) | |||||||||||||
| Outstanding at December 31, 2020 | 5,895,570 | 3.41 | 5.68 | 1,460,507 | ||||||||||||
| Forfeited | (2,730,571 | ) | 2.75 | |||||||||||||
| Outstanding at March 31, 2021 | 3,164,999 | 2.18 | 5.22 | 2,350,775 | ||||||||||||
| Vested and exercisable at March 31, 2021 | 1,352,499 | 1.98 | 5.17 | 1,251,775 | ||||||||||||
The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected term of the stock options. The ranges of assumptions used in the Black-Scholes Model during the three months ended March 31, 2020 is set forth in the table below:
| Three Months Ended | ||||
| March 31, 2020 | ||||
| Risk-free interest rate | 1.67 | % | ||
| Expected term in years | 4.27 | |||
| Weighted Avg. Expected Volatility | 107.73 | % | ||
| Expected dividend yield | 0 | % | ||
The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term. Estimated volatility is a measure of the amount by which the stock price is expected to fluctuate each year during the term of an award. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. The average expected life is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Future stock-based compensation may significantly differ based on changes in the fair value of our Common Stock and our estimates of expected volatility and the other relevant assumptions.
| 9 |
The following table sets forth the share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in the Company’s Statements of Operations for the three months ended March 31, 2021 and 2020:
| Three Months Ended March 31, | ||||||||
| 2021 | 2020 | |||||||
| Research and development | $ | 278,815 | $ | - | ||||
| General and administrative | (1,153,575 | ) | 465,763 | |||||
| Total | $ | (874,760 | ) | $ | 465,763 | |||
Three Months Ended March 31, 2021
During our first quarter 2021, certain individuals resigned from the Company resulting in the forfeiture and cancellation of 2,730,571 options. Compensation expense was recorded on these options prior to their full vesting. As a result, the Company recognized a $1,248,575 reversal of the prior recognized compensation expense related to the cancelled options. The expensed recognized for options still in their vesting period totaled $373,815 ($278,815 in R&D expense and $95,000 in G&A expense).
Note 6. Leases
The Company determines if an arrangement is a lease, or contains a lease, at the inception of an arrangement. If the Company determines that the arrangement is a lease, or contains a lease, at lease inception, it then determines whether the lease is an operating lease or finance lease. Operating and finance leases result in recording a right-of-use (“ROU”) asset and lease liability on the consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. For purposes of calculating operating lease ROU assets and operating lease liabilities, the Company uses the non-cancellable lease term plus options to extend that it is reasonably certain to exercise. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term. The Company’s leases generally do not provide an implicit rate. As such, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company has elected not to recognize ROU assets and lease liabilities that arise from short-term (12 months or less) leases for any class of underlying asset. The Company has elected not to separate lease and non-lease components for any class of underlying asset.
In February 2020, the Company entered into a two-year lease for office premises located at 4 Becker Farm Road, Suite 105, Roseland, New Jersey. Monthly base rent in year one of the lease is $4,356; and $4,459 in year 2 of the lease. The term (and payment of the monthly rent) commences upon substantial completion of the landlord’s work, which was expected to occur on or before May 31, 2020. Due to the COVID-19 pandemic the lease term commenced on August 1, 2020.
The Company does not have any finance leases.
Supplemental lease information as of March 31, 2021:
| As of March 31, 2021 | As of December 31, 2020 | |||||||
| Operating lease right-of-use asset | $ | 65,603 | $ | 79,462 | ||||
| Current maturities of operating lease | $ | 49,943 | $ | 51,125 | ||||
| Non-current operating lease | 17,579 | 28,607 | ||||||
| Total operating lease liabilities | $ | 67,522 | $ | 79,732 | ||||
| Weighted Average remaining lease term (in years): | 1.34 | 1.6 | ||||||
| Discount rate: | 7.0 | % | 7.0 | % | ||||
| 10 |
Supplemental cash flow information for the three months ended March 31, 2021:
| Cash paid for amount included in the measurement of lease liabilities for operating lease | $ | 13,068 | ||
| Right-of-use asset obtained in exchange for lease obligation | $ | 98,402 |
The Company leases office space under a non-cancellable operating lease expiring in 2022. Future lease payments included in the measurement of lease liabilities on the balance sheet at March 31, 2021 for future periods are as follows:
| Years ending December 31, 2021, | ||||
| 2021 (Remaining) | $ | 39,720 | ||
| 2022 | $ | 31,213 | ||
| Total future minimum lease payments | $ | 70,933 | ||
| Less imputed interest | $ | 3,411 | ||
| Total | $ | 67,522 | ||
Note 7. Commitments
In connection with the Company’s anticipated regulatory filings, the Company has engaged StemCell Systems GmbH (“StemCell Systems”) to provide it with prototypes and related documents under various agreements. On July 1, 2020, the Company and StemCell Systems entered into a Strategic R&D Agreement (the “Strategic Agreement”) having an initial term of three years with successive one-year extensions unless earlier terminated. The Strategic Agreement includes a $27,000 monthly fee to be paid to StemCell Systems along with any additional expenses incurred. The Company, StemCell Systems and certain affiliates of StemCells entered into a Rights of First Refusal and Corporate Opportunities Agreement (the “ROFR Agreement”). Pursuant to the ROFR Agreement, (i) in the event a StemCell Systems stockholder receives an offer from a third party to acquire the StemCell Systems stockholders ownership interest, the Company shall have ten business days to purchase such ownership, and (ii) if during the terms of the Strategic Agreement, any StemCell Systems inventions, with respect to skin, burns and wounds, designs, inventions and among other things, whether or not patentable, copyrightable or otherwise legally protectable are discovered by StemCell Systems, the Company shall have the first option to negotiate mutually agreeable terms for the Company’s acquisition or licensing of the StemCell Systems inventions. Pursuant to these engagements the Company incurred expenses of approximately $120,000 and $76,000 during the three months ended March 31, 2021 and 2020, respectively.
Note 8. Related Party Transactions
During the three months ended March 31, 2020, Talia Jevan Properties, Inc. made payments totaling $5,287 to Stephen Yan-Klassen, former CFO who resigned in 2020, for his salary on behalf of the Company. Talia Jevan Properties, Inc. is a related party of Harmel S. Rayat, Chairman of the Board.
On August 1, 2013, the Company entered into a consulting agreement, as amended on May 1, 2016, with Jatinder Bhogal, an individual owning in excess of 5% of the Company’s issued and outstanding shares of common stock, to provide consulting services to the Company through his wholly owned company, Vector Asset Management, Inc. (“VAMI”). Pursuant to the consulting agreement, VAMI assisted the Company with identifying subject matter experts in the medical device and biotechnology industries and assisted the Company with its ongoing research, development and eventual commercialization of its Regeneration Technology. Pursuant to an amendment dated May 1, 2016, the VAMI monthly consulting fee was increased from $5,000 to $6,800. On June 22, 2018, the Company and VAM entered into an Executive Consulting Agreement (the “ECA”) pursuant to which Mr. Bhogal served as the Company’s Chief Operating Officer. The ECA supersedes the prior consulting agreement. Pursuant to the ECA, VAMI received compensation of $120,000 per year. On July 1, 2020 the Company amended the ECA and paid VAMI $4,000 per month through November 30, 2020 and $200 per month thereafter until May 31, 2021 at which time the agreement will expire. During the three months ended March 31, 2021 and 2020, the Company recognized expenses of $600 and $30,000 for consulting services provided by VAMI. Jatinder Bhogal resigned as the Company’s COO effective June 30, 2020.
Note 9. Subsequent Events
Management has reviewed material events subsequent of the period ended March 31, 2021 and prior to the filing of financial statements in accordance with FASB ASC 855 “Subsequent Events”.
| 11 |
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Cautionary Note Regarding Forward-Looking Statements
This discussion and analysis of financial condition and results of operations is based upon and should be read in conjunction with the unaudited interim consolidated financial statements of RenovaCare, Inc. (“RenovaCare”) and its wholly-owned subsidiary (collectively with RenovaCare, “we,” “our,” “us,” or the “Company”), appearing elsewhere in this Quarterly Report on Form 10-Q, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of any contingent liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. On an on-going basis the Company reviews its estimates and assumptions. The estimates were based on historical experience and other assumptions that the Company believes to be reasonable under the circumstances. Actual results are likely to differ from those estimates under different assumptions or conditions, but we do not believe such differences will materially affect our financial position or results of operations. Critical accounting policies, the policies the Company believes are most important to the presentation of its financial statements and require the most difficult, subjective and complex judgments, are outlined below in “Critical Accounting Policies,” and have not changed significantly since 2020.
This Quarterly Report on Form 10-Q also contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, as well as information relating to the Company that is based on management's exercise of business judgment and assumptions made by and information currently available to management. Although forward-looking statements in this Quarterly Report on Form 10-Q reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. When used in this document and other documents, releases and reports released by us, the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “the facts suggest” and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect our current view of future events and are subject to certain risks and uncertainties as noted below. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results could differ materially from those anticipated in these forward-looking statements. Actual events, transactions and results may materially differ from the anticipated events, transactions or results described in such statements. Although we believe that our expectations are based on reasonable assumptions, we can give no assurance that our expectations will materialize. Many factors could cause actual results to differ materially from our forward-looking statements and unknown, unidentified or unpredictable factors could materially and adversely impact our future results. We undertake no obligation and do not intend to update, revise or otherwise publicly release any revisions to our forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of any unanticipated events. Several of these factors include, without limitation:
| · | our ability to meet requisite regulations or receive regulatory approvals in the United States, and our ability to retain any regulatory approvals that we may obtain; and the absence of adverse regulatory developments in the United States and abroad; | |
| · | new entrance of competitive products or further penetration of existing products in our markets; | |
| · | results of our clinical trials; | |
| · | failure of our products to gain market acceptance; | |
| · | the cost and success of our development programs; | |
| · | our failure to obtain financing as, if and when needed, on commercially acceptable terms; | |
| · | our failure to attract and retain qualified personnel; | |
| · | our failure to adequately manage our growth and expansion; | |
| · | the effect on us from adverse publicity related to our products or the Company itself; and | |
| · | our failure to defend against any adverse claims relating to our intellectual property. |
| 12 |
The safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, apply to forward-looking statements made by us. The reader is cautioned that no statements contained in this Form 10-Q should be construed as a guarantee or assurance of future performance or results. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors, including, without limitation, the risks described in this report and matters described in this report generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this filing will in fact occur.
Overview
We are a development-stage biotechnology and medical device company focusing on the research, development and commercialization of autologous (using a patient's own cells) cellular therapies that can be used for medical and aesthetic applications. The Company does not have any commercialized products. The Company's activities have consisted principally of performing research and development activities, business development efforts, and raising capital to support such activities.
The Company, through its wholly owned subsidiary, RenovaCare Sciences Corp., owns the CellMist™ System which is a cell isolation procedure that enzymatically renders stem cells from the patient’s own skin or other tissues. The resulting stem cell suspension is administered topically with our SkinGun™ spray device as a cell therapy onto wounds including burns to facilitate healing.
In August 2020, the Company announced that the US Food and Drug Administration (FDA) conditionally approved the Company’s Investigational Device Exemption (IDE) application to conduct a clinical trial that will evaluate the safety and feasibility of autologous skin and pluripotent stem cells rendered by its manual CellMist™ System from donor skin and applied topically with the electronic SkinGun™ spray device for treatment of acute burn wounds. The clinical trial protocol is an open-label single-arm clinical study that will enroll 14 adult human burn subjects with partial-thickness, second-degree thermal burn wounds covering between 10% and 30% total body surface area. The Company expects to conduct the clinical study at four (4) U.S. burn centers commencing in the second quarter of 2021.
The development of our new closed, automated cell isolation device for the CellMistTM System is in the early stage, and we expect significant time and resources will be devoted to develop our technology and determine the commercial feasibility of the product. Research and development of new technologies involve a high degree of risk, and there is no assurance that our development activities will result in a commercially viable product. The long-term profitability of our operations will be, in part, directly related to the cost and success of our development programs, which may be affected by a number of factors.
The Company has not generated any revenue and has sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues development of its products and technologies and expects that it will need to raise additional capital through partnerships or the sale of its securities to accomplish its business plan. Failing to secure such additional funding before achieving sustainable revenue and profit from operations poses a significant risk. The Company's ability to fund the development of its cellular therapies depends on the amount and timing of cash receipts from future financing activities. There can be no assurance as to the availability or terms upon which such financing and capital might be available.
Additionally, there is significant uncertainty relating to the full impact of the COVID-19 pandemic on the Company’s operations and capital requirements. Should financing when needed be unavailable or prohibitively expensive or the COVID-19 pandemic continue, it may adversely affect the Company’s ability to (i) retain employees and consultants; (ii) obtain additional financing on terms acceptable to the Company, if at all; (iii) delay regulatory submissions and approvals; (iv) delay, limit or preclude the Company from the operation of clinical study sites and testing laboratories; (v) delay, limit or preclude the Company from achieving technology or product development goals, milestones, or objectives; and (vi) preclude or delay entry into joint venture or partnership arrangements. The occurrence of any one or more of such events may affect the Company’s ability to continue its pathway to commercialization of its technology or products.
| 13 |
Components of Our Results of Operations
Revenue
To date we have not generated any product revenues and do not expect to generate any revenue for the foreseeable future. Our ability to generate revenue and become profitable depends upon our ability to obtain marketing approval and successfully commercialization of our CellMistTM System.
Research and Development
Research and development (“R&D”) expenses consist primarily of costs incurred for the development of our CellMistTM System and include:
| · | pilot-scale manufacturing of our cell isolation and SkinGunTM spray devices. |
| · | employee-related expenses associated with our research and development activities, including salaries, benefits, travel and non-cash stock-based compensation expenses. |
| · | costs associated with regulatory operations and regulatory compliance. |
| · | expenses incurred under agreements related to our clinical trials. |
| · | other research and development costs including contract consulting fees and non-cash stock-based compensation to contract research organizations (CROs) and other third parties. |
We do not believe that it is possible at this time to accurately project total expenses required for us to reach commercialization of our CellMistTM System. In the future, we expect that research and development expenses will increase due to our ongoing product development and approval efforts. We expense research and development costs as incurred.
General and Administrative
General and administrative expenses consist primarily of personnel costs, including non-cash stock-based compensation related to directors and employees, professional service costs including legal, accounting, and other consulting fees and other general and administrative expenses including investor relations, insurance, and facilities costs. We expect general and administrative expenses to increase in the future as we hire personnel and incur additional costs to support the expansion of our research and development activities and our operation as a public company.
Other Income (Expense)
Other income consists of interest income earned on our cash and cash equivalents.
Income Taxes
We have yet to generate taxable income. We have historically incurred operating losses resulting in carry forward tax losses totaling approximately $22.3 million as of December 31, 2020. We anticipate that we will continue to generate tax losses for the foreseeable future and that we will be able to carry forward these tax losses indefinitely to future taxable years. Accordingly, we do not expect to pay taxes until we have taxable income after the full utilization of our carry forward tax losses. We have provided a full valuation allowance with respect to the deferred tax assets related to these carry forward losses.
| 14 |
Results of Operations
Comparison of Three Months Ended March 31, 2021 and March 31, 2020
Research and Development Expenses
| Three Months Ended March 31, | Increase / | |||||||||||
| 2021 | 2020 | (Decrease) | ||||||||||
| Manufacturing clinical supplies | $ | 216,183 | $ | - | $ | 216,183 | ||||||
| Personnel related | 154,175 | 85,216 | 68,959 | |||||||||
| Stock-based compensation | 278,813 | - | 278,813 | |||||||||
| Clinical trials | 306,356 | - | 306,356 | |||||||||
| Regulatory | 9,832 | 11,525 | (1,693 | ) | ||||||||
| All other | 88,934 | 96,032 | (7,098 | ) | ||||||||
| $ | 1,054,293 | $ | 192,773 | $ | 861,520 | |||||||
Total research and development expenses increased by $0.9 million from $0.2 million during the three months ended March 31, 2020 to $1.1 million during the three months ended March 31, 2021. Manufacturing clinical supplies increased $0.2 million due to the pilot-scale manufacturing and validation testing of the components of the CellMist™ System and the electronic SkinGun™ spray device to be used in our clinical trials. Personnel related expenses, including stock-based compensation, increased $0.3 million due to the hiring of new R&D leadership to support the development of our CellMist™ System. Clinical trial expenses increased $0.3 million due to the addition of clinical professionals and costs related to the preparation of our clinical trials which we expect to begin in the second quarter of 2021. We expect clinical trial expenses to increase significantly in 2021 due to patient enrollment, treatment, follow-up visits, and medical site monitoring. All other expenses decreased $7 thousand, as validation testing for the electronic SkinGun ™ concludes and we transition to prototype development of the cell isolation device at StemCell Systems.
General and Administrative Expenses
| Three Months Ended March 31, | Increase / | |||||||||||
| 2021 | 2020 | (Decrease) | ||||||||||
| Personnel related | 208,684 | 188,451 | 20,233 | |||||||||
| Stock-based compensation | (1,153,575 | ) | 465,763 | (1,619,338 | ) | |||||||
| Professional and consultant fees | 283,791 | 259,743 | 24,048 | |||||||||
| All other | 124,056 | 121,609 | 2,447 | |||||||||
| Total general and administrative expenses | (537,044 | ) | 1,035,566 | (1,572,610 | ) | |||||||
General and administrative expenses decreased by $1.6 million from a loss of $1.0 million for the three months ended March 31, 2020 to a gain of $0.6 million for the three months ended March 31, 2021. Excluding stock-based compensation, general and administrative expenses increased by $47 thousand.
Stock-Based Compensation
Expense associated with equity based transactions is calculated and expensed in our financial statements as required pursuant to various accounting rules and is non-cash in nature. Stock compensation represents the expense associated with the amortization of our stock options. Stock compensation expense decreased during the quarter ended March 31, 2021 compared to 2020 primarily due to the forfeiture and cancellation of 2,730,571 stock options as a result of the resignation of Alan Rubino, the Company’s former Chairman, President and Chief Executive Officer and the termination of his employment agreement, and the removal, by the Company’s stockholders of Kenneth Kirkland and Lydia Evans, as members of the Company’s Board of Directors. Compensation expense was recorded on these options prior to their full vesting. As a result, the Company recognized a $1,248,575 reversal of the prior recognized compensation expense related to the cancelled options. The expense recognized for options still in their vesting period totaled $373,815.
| 15 |
Liquidity and Capital Resources
The Company does not have any commercialized products, has not generated any meaningful revenue since inception and has sustained recurring losses and negative cash flows since inception. The Company has incurred operating losses of $0.5 million and $1.2 million during the three months ended March 31, 2021 and 2020, respectively. The Company expects to incur losses as it continues development of its products and technologies. Historically, the Company has been funded through the sale of equity securities and debt financings. As of March 31, 2021, the Company had $5.6 million of cash. The Company believes that it currently has sufficient cash to meet its funding requirements over the next year.
Net cash used in operating activities was $1.8 million during the three months ended March 31, 2021, primarily due to operating costs of $1.3 million and the payment of liabilities of approximately $0.5 million.
Net cash used in investing was $0 for the three months ended March 31, 2021 and $8 thousand for the three months ended March 31, 2020.
There was no net cash used in financing activities during the three months ended March 31, 2021 and 2020.
Fair Value of Financial Instruments and Risks
The carrying value of cash and cash equivalents, accounts payable, and contract and contribution payable, approximate their fair value because of the short-term nature of these instruments and their liquidity. It is not practical to determine the fair value of the Company’s notes payable and accrued interest due to the complex terms. Management is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments.
Market Risk Disclosures
We have not entered into derivative contracts either to hedge existing risks or for speculative purposes during the three months ended March 31, 2021 or year ended December 31, 2020, and the subsequent period through the date of this report.
Off-Balance Sheet Arrangements and Contractual Obligations
We do not have any off-balance sheet arrangements or contractual obligations at March 31, 2021, and the subsequent period through the date of this annual report, that are likely to have or are reasonably likely to have a material current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that have not been disclosed in our consolidated financial statements.
Recently Accounting Standards
See Note 1 to our Consolidated Financial Statements for more information regarding recent accounting standards and their impact to our consolidated results of operations and financial position.
Related Party Transactions
During the three months ended March 31, 2021, Talia Jevan Properties, Inc. made payments totaling $5,287 to Stephen Yan-Klassen, former CFO who resigned in 2020, for his salary on behalf of the Company. Talia Jevan Properties, Inc. is a related party of Harmel Rayat, Chairman of the Board.
On August 1, 2013, the Company entered into a consulting agreement, as amended on May 1, 2016, with Jatinder Bhogal, an individual owning in excess of 5% of the Company’s issued and outstanding shares of common stock, to provide consulting services to the Company through his wholly owned company, Vector Asset Management, Inc. (“VAMI”). Pursuant to the consulting agreement, VAMI assisted the Company with identifying subject matter experts in the medical device and biotechnology industries and assisted the Company with its ongoing research, development and eventual commercialization of its Regeneration Technology. Pursuant to an amendment dated May 1, 2016, the VAMI monthly consulting fee was increased from $5,000 to $6,800. On June 22, 2018, the Company and VAM entered into an Executive Consulting Agreement (the “ECA”) pursuant to which Mr. Bhogal served as the Company’s Chief Operating Officer. The ECA supersedes the prior consulting agreement. Pursuant to the ECA, VAMI received compensation of $120,000 per year. On July 1, 2020 the Company amended the ECA and paid VAMI $4,000 per month through November 30, 2020 and $200 per month thereafter until May 31, 2021 at which time the agreement will expire. During the three months ended March 31, 2021 and 2020, the Company recognized expenses of $600 and $30,000 for consulting services provided by VAMI. Jatinder Bhogal resigned as the Company’s COO effective June 30, 2020.
| 16 |
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Not applicable.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined as a process designed by, or under the supervision of, our principal executive and principal financial officers, or persons performing similar functions, and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
The Company maintains “disclosure controls and procedures,” as such term is defined under Rule 13a-15(e) and 15d-15(e) of the Exchange Act, that are designed to provide reasonable assurance that information required to be disclosed in the Company’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Our management conducted an evaluation of the effectiveness of the Company’s internal control over financial reporting based on the framework in “Internal Control — Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this evaluation, management concluded that our internal control over financial reporting was not effective at March 31, 2021 because of the material weaknesses described below.
There is inadequate segregation of duties consistent with control objectives. Our Company’s management is comprised of a very small number of individuals resulting in a situation where limitations of segregation of duties exist. In order to remedy this situation, we would need to hire additional staff to provide greater segregation of duties. In addition, management has concluded that there are ineffective monitoring controls related to the financial close and reporting process, including management’s risk assessment process and its identification, evaluation, and timely remediation of control deficiencies.
Accordingly, as a result of identifying the above material weakness we have concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by the Company’s internal controls.
| 17 |
Management believes that the material weaknesses set forth above were the result of the scale of our operations and are intrinsic to our small size.
Management believes these weaknesses did not have a material effect on our financial results and intends to take remedial actions as we further develop our technology.
Changes in Internal Control over Financial Reporting
There were no changes in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), or in factors that could materially affect internal controls, during the three months ended March 31, 2021, or subsequent to the date that management completed their evaluation, that materially affected, or are reasonably likely to materially affect, our internal control over financing reporting.
None.
Smaller reporting companies are not required to provide the information required by this item.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
| 18 |
| Exhibit No. | Description of Exhibit | |
| 10.1 | Separation and Release of Claims Agreement dated March 26, 2021, incorporated by reference and included in the Company’s Form 8-K filed on March 30, 2021. | |
| 31.1 | Certification of the Principal Executive Officer pursuant to Rule 13a-14(a).* | |
| 31.2 | Certification of the Principal Financial Officer pursuant to Rule 13a-14(a).* | |
| 32.1 | Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* | |
| 101.INS | XBRL Instance Document** | |
| 101.SCH | XBRL Taxonomy Extension - Schema Document** | |
| 101.CAL | XBRL Taxonomy Extension - Calculation Linkbase Document** | |
| 101.DEF | XBRL Taxonomy Extension - Definition Linkbase Document** | |
| 101.LAB | XBRL Taxonomy Extension - Label Linkbase Document** | |
| 101.PRE | XBRL Taxonomy Extension - Presentation Linkbase Document** |
_______________
| * | Filed herewith. |
| ** | Furnished herewith. XBRL (eXtensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections. |
| 19 |
Pursuant to the requirements of Sections 13 or 15 (d) of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
RenovaCare, Inc.
(Registrant)
| Date: May 7, 2020 | By: | /s/ Kaiyo Nedd |
| Name: | Dr. Kaiyo Nedd | |
| Title: | Chief Executive Officer | |
| Date: May 7, 2020 | By: | /s/ Justin Frere, |
| Name: | Justin Frere, CPA | |
| Title: | Chief Financial Officer |
20